Weight loss drugs could make oral contraception less effective, MHRA warns: [accessed 20 March 2026] EMC (2024)
Oral GLP-1 formulations coming to market in 2026 may offer even more cost flexibility, although leading products like semaglutide and tirzepatide are unlikely to face generic competition until the next decade
October 9, 2024: FDA Announces End of Terzepatide Shortage
For example, a randomized, double-blind, placebo-controlled trial involving 54 elderly participants reported significant increases in muscle performance without any noted side effects ( Beyond its well-established hepatoprotective effects, Schisandra chinensis has demonstrated promising therapeutic potential in other areas, including neuroprotection, cardioprotection, and gut microbiota regulation
Article PubMed Google Scholar Herring, W